Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Immunotherapy remains one of the most active areas of drug development for neurodegenerative diseases. AD/PD 2026 featured extensive coverage of antibody-based therapies, active immunization approaches, and next-generation engineering strategies for both Alzheimer's and Parkinson's diseases[@schneider2024].
The first fully approved disease-modifying therapy for early AD:
- CLARITY-AD Results: Continued demonstration of clinical benefit
- Long-Term Extension: 36-month data showing sustained effects
- Real-World Evidence: Post-approval effectiveness data
- Safety Management: ARIA monitoring protocols and real-world incidence
- Combination Strategies: Trials combining lecanemab with other modalities
Trailingblazer program continues to evolve:
- TRAILBLAZER-ALZ 2: Results in broader patient populations
- Biomarker Correlations: Amyloid plaque reduction predicts clinical outcomes
- Treatment Sequencing: Managing patients before and after treatment
- Safety Profile: Managing ARIA in clinical practice
- Gantenerumab - Roche: Reformulated delivery and new trial designs
- Crenezumab - Roche: Anti-amyloid approaches in early populations
- Remternetug - Lilly: Next-generation anti-amyloid antibodies
Tau immunotherapy has matured significantly[@danysz2023]:
- Phase 2 Results: Safety and efficacy data in early AD
- Mechanism of Action: Targeting extracellular tau species
- Biomarker Endpoints: Tau PET and fluid biomarker correlations
- First-in-Human Studies: Early safety and pharmacokinetics
- Target Profile: Optimal epitope selection
- APNmAb05: Early-stage anti-tau antibody
- Tau PET Correlations: Imaging-based patient selection
- LMTM - TauRx: Phase 3 results and regulatory status
- Novel Small Molecules: Next-generation aggregation inhibitors
Alpha-synuclein antibodies represent a major focus for PD[@masliah2023]:
- Clinical Development: Subcutaneous anti-alpha-synuclein antibody
- Mechanism: Targeting toxic alpha-synuclein aggregates
- PD Research: Focused on early-stage patients
- Phase 2 Results: Safety and efficacy data in early PD
- Motor Outcomes: Effects on motor symptoms
- Biomarker Correlations: Alpha-synuclein seed amplification
- Active Immunization: Vaccine approach for alpha-synuclein
- Immune Response: Antibody generation against alpha-synuclein
- Safety Profile: Initial clinical data
¶ Next-Generation Antibody Engineering
- Tau-Amyloid Bispecifics: Dual-targeting approaches
- Antibody-Therapeutic Conjugates: Enhanced brain penetration
- Cross-Disease Applications: Antibodies for both AD and PD targets
- Half-Life Extension: Modified Fc regions for reduced dosing
- Effector Function Modulation: Optimizing safety profiles
- Blood-Brain Barrier Penetration: Engineering for enhanced CNS delivery
- Biomarker-Driven Selection: Amyloid and tau PET for patient selection
- Genetic Stratification: Targeting specific genetic subpopulations
- Stage-Specific Approaches: Optimizing for early vs. advanced disease
- Immunotherapy + Small Molecule: Combining antibody therapy with oral drugs
- Immunotherapy + Gene Therapy: Novel combination strategies
- Multi-Antibody Combinations: Simultaneous targeting of multiple proteins
¶ Safety and Biomarkers
- Monitoring Protocols: Advanced MRI and clinical monitoring
- Risk Factors: Identifying patients at highest risk
- Management Strategies: Best practices for ARIA handling
- p-Tau217: Regulatory qualification for trial enrichment
- Amyloid PET: Standardized approaches for patient selection
- Tau PET: For anti-tau therapy development
- Anti-amyloid validates — Leqembi and donanemab showing sustained benefits
- Anti-tau maturing — Multiple antibodies in late-stage development
- α-Synuclein advancing — Active programs in Parkinson's disease
- Engineering improving — Next-generation antibodies with enhanced properties
- Combination emerging — Immunotherapy combinations in early development